Background: Disease activity of rheumatoid arthritis (RA) is evaluated by composite measures, such as Disease Activity Score (DAS). Recently, much attention has been paid to a neutrophil-lymphocyte (N/L) ratio to evaluate the prognosis and the efficacy of intervention in various diseases. To determine whether the N/L ratio is a prognostic marker or a surrogate marker of response to biologics, this study investigated the N/L ratio in RA patients treated with biological agents.
Introduction
Rheumatoid arthritis (RA) is an inflammatory disease that causes devastating joint destruction if patients are not appropriately treated. Because no single measure is available to correctly estimate the disease activity of RA, composite measures that have been used include the 28joint Disease Activity Score (DAS28), the Simplified Disease Activity Index, and the Clinical Disease Activity In-dex 1, 2 . Since the start of this century, RA and other rheumatic diseases have treated with biological agents. Although such biologics show effects on RA superior to those of conventional synthetic disease-modifying antirheumatic drugs, their high-cost and adverse events have been significant concerns 3 . To administer expensive biologics in clinical practice, measuring disease activity and then evaluating drug efficacy are important. The DAS28- To evaluate the prognosis and the effectiveness of treatment in various diseases, the use of the neutrophillymphocyte (N/L) ratio has been reported 4 11 . Patients with RA have a higher N/L ratio than do subjects without RA 12 . To determine whether the N/L ratio is a prognostic marker or a surrogate marker of the response to biologics, in the present study we investigated the N/L ratio and its change in patients with RA treated with biologics.
Patients and Methods
This retrospective study reviewed the medical records of patients with RA who had received routine care at Nippon Medical School. The patients had been treated with a single biologic agent for at least 6 months ( Table 1) Finally, the implication of the N/L ratio in the response to treatment were examined.
Statistical Analysis
Values are expressed as means and standard devia- 
Results
Of the 358 patients, 288 were naïve to biologics ( Table 1) . From baseline to after 6 months of treatment, the mean neutrophil count and the mean N/L ratio among all patients decreased significantly (P<0.01) and that of the lymphocyte count increased significantly (P<0.01) ( Table   2 ). The N/L ratio and the DAS28-ESR were modestly but significantly correlated (r=0.18, P<0.01) at baseline ( Fig. 1   A) . The N/L ratio in patients with high disease activity was greater than that in patients with low disease activity (Fig. 2) . The N/L ratio and the DAS28-ESR after 6 months of treatment were also significantly correlated (r= 0.37, P<0.01) (Fig. 1B) .
The N/L ratio decreased after treatment with biological agents and the decrease was significant, except for abatacept ( Fig. 3) . ΔN/L ratio and ΔDAS28-ESR showed modest but significant correlation (r=0.23, P<0.01) (Fig.   4) . The ΔN/L ratio was found to be modestly but significantly correlated with the ΔCRP (r=0.17, P<0.01) and the ΔDAS28-CRP (r=0.25, P<0.01) ( Table 3 ). The ΔESR strongly correlated with ΔDAS28-ESR. In addition to ΔESR, other variables, such as ΔCRP, ΔMMP-3, the change of the white blood count and the change of the neutrophil count, correlated modestly but significantly with the ΔDAS28-ESR ( Table 4 ).
The N/L ratio at baseline showed no significant difference with regard to the response criteria, but the N/L ratio after 6 months of treatment and the ΔN/L ratio showed significant differences between patients with a good response and those with no response (Fig. 5) . Thus, the pretreatment N/L ratio was not a prognostic marker of response to biologics at baseline but did reflect the re- At baseline the mean neutrophil count and the mean N/L ratio were significantly greater (both P<0.01) and the mean lymphocyte count was significantly lower (P< 0.05) in patients who received prednisolone than in patients who did not ( Table 2) . However, from baseline to after 6 months of treatment in both groups of patients, the neutrophil count and the N/L ratio decreased significantly (both P<0.01) and the lymphocyte count increased significantly (P<0.01) ( Table 2 ). The dosage of prednisolone was tapered in 60 of 258 patients because disease activity was found to have decreased. Between baseline and after 6 months of treatment, both the neutrophil count and the N/L ratio decreased significantly and the lymphocyte count increased significantly in these 60 patients ( Table 2) . Furthermore, ΔN/L and ΔDAS28-ESR were significantly correlation both in patients who had received prednisolone (r=0.23, P<0.01) and in patients who had not (r=0.22, P<0.01). Prednisolone did not affect the prognostic role of the N/L ratio (data not shown).
In patients who received methotrexate, the N/L ratio at baseline was significantly lower (6.0 3.2) than in patients who did not receive methotrexate (7.0 3.7, P< 0.05). However, treatment with methotrexate did not affect the correlation between ΔN/L and ΔDAS28-ESR or the prognostic value of the pretreatment N/L ratio.
Discussion
In Furthermore, the N/L ratio is positively correlated with the expression of CD10 and CD35 as a result of neutrophil activation 15 .
A recently study has found that the N/L ratio is higher in patients with RA (2.12) than in healthy subjects (0.83), is correlated with DAS28 (r=0.345, P<0.0001), and is higher in patients with active disease 12 have been reported to reflect the disease activity of RA 16 .
We also found that the N/L ratio decreased after treatment with each biological agent, except for abatacept. In the present study we also examined whether the N/ L ratio can predict a response to biological agents. Disappointingly, the pretreatment N/L ratio did not predict the response to treatment. Several biomarkers, such as baseline tumor necrosis factor levels 17 , circulating T helper 17 cells and interleukin 17 18 , and interleukin 1β levels from stimulated WBC, have been studied as predictors of tumor necrosis factor inhibitor 19 ; however, no robust biomarker has been identified. In the present study we observed that the ΔN/L ratio was larger and the N/L ratio after 6 months of treatment was lower in patients with a good response. This result indicates again that the N/L ratio reflects disease activity and decreases when disease activity decreases. Moreover, ΔN/L ratio correlated with CRP-related measures (CRP and DAS28-CRP) rather than with ESR ( Table 3) . Although ΔDAS28-ESR correlated strongly with ΔESR, it also correlated modestly with ΔCRP, ΔMMP-3, ΔWBC, the change of the neutrophil count, and ΔN/L ratio ( Table 4 ).
In conclusion, the present study has found that the N/ L ratio is a marker of disease activity in RA and that the ΔN/L ratio reflects the efficacy of biological agents. However, the pretreatment N/L ratio does not predict the response to biological agents.
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